Evidence map›Paper›PMID 9677334›Full record

ArticleThe Biochemical journal1998

Human thrombopoietin structure-function relationships: identification of functionally important residues.

A Jagerschmidt, V Fleury, M Anger-Leroy, C Thomas, M Agnel, D P O'brien

Open access · bronzeAbstract read
In one paragraph

Article in The Biochemical journal, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Structural basis of MPL activation by thrombopoietin.Blood vessels, thrombosis & hemostasis · 2024
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. The molecular mechanisms that control thrombopoiesis.The Journal of clinical investigation · 2005
    Review
  7. Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment.Proceedings of the National Academy of Sciences of the United States of America · 2004
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

A JagerschmidtSynthélabo Recherche, Department of Genomic Biology, 10 rue des Carrières, 92500 Rueil-Malmaison, France.
V Fleury
M Anger-Leroy
C Thomas
M Agnel
D P O'brien

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thrombopoietin (TPO) is a haematopoietic growth factor responsible for megakaryocyte progenitor proliferation and differentiation. It belongs to the four-helix-bundle cytokine family and exerts its biological effects through binding to a specific receptor, c-Mpl. With the use of site-directed mutagenesis we have generated 20 TPO mutants. Each of the TPO mutants was produced in a eukaryotic expression system and the mutants' ability to induce the proliferation of factor-dependent c-Mpl-expressing megakaryoblastic M-O7e cells was compared with that of wild-type TPO. Among the mutations studied, 10 lead to a significant decrease in TPO bioactivity. Of these ten residues, three are located in helix A of the protein (Arg10, Lys14 and Arg17) and four in helix D (His133, Gln132, Lys138 and Phe141), indicating that in TPO, as in other cytokines, these two helices are important for functional cytokine/receptor interactions. Surprisingly, mutant Arg10-->Ala (R10A) lacked any proliferative activity, despite the fact that this mutation was recently reported to have no effect on TPO/c-Mpl binding in a TPO phage ELISA [Pearce, Potts, Presta, Bald, Fendly and Wells (1997) J. Biol. Chem. 272, 20595-20602]. The lack of M-O7e proliferation is probably due to an inability of R10A mutant to promote receptor dimerization and thus receptor activation. Moreover we found that the Arg10 and Arg17 residues of TPO seem to be specific determinants for TPO/c-Mpl recognition. We also demonstrate that the O-glycosylation site located at position 110 of TPO is not necessary for the bioactivity of the cytokine.

Indexed as

Neoplasm ProteinsProtein Structure, SecondaryReceptors, CytokineAmino Acid SequenceBinding SitesCell DivisionHumansMegakaryocytesMolecular Sequence DataMutagenesis, Site-DirectedMutationProto-Oncogene ProteinsReceptors, ThrombopoietinSequence Homology, Amino AcidSolubilityStructure-Activity RelationshipMPL protein, humanNeoplasm ProteinsProto-Oncogene ProteinsReceptors, CytokineReceptors, ThrombopoietinThrombopoietin

Identifiers

PMID9677334
PMCPMC1219638
OpenAlexW1862189597

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.